Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
Material Changes
On October 24, 2013, Mr. R G Connor, a PDMR, executed the following transactions:
- Exercised options over 4,500 Ordinary Shares granted on October 28, 2003, at an exercise price of £12.68 per share.
- Sold 4,500 Ordinary Shares at a price of £15.67 per share.
- Sold an additional 3,400 Ordinary Shares at a price of £15.67 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It is a statutory disclosure of insider trading activity.
Investor Verification Checklist
- Verify the total number of shares sold by Mr. R G Connor (7,900 shares total).
- Confirm the exercise price (£12.68) versus the sale price (£15.67) to calculate realized gains.
- Check subsequent filings for any changes in Mr. Connor's remaining shareholding.